3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
12
Neoplasm Metastasis
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm, Residual
1
Mouth Neoplasms
1
Melanoma
1
Liver Neoplasms
1
Head and Neck Neoplasms
1
HER2-positive Gastric Cancer
1
HER2-positive Breast Cancer
1
HER2-positive Advanced Gastric Cancer
1
HER2 Overexpression
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Drug-Related Side Effects and Adverse Reactions
1
Interventions
Surveys and Questionnaires
34
Blood Specimen Collection
24
enzalutamide
18
Radiotherapy
15
Docetaxel
15
Biopsy
14
Abiraterone Acetate
14
apalutamide
13
Leuprolide
13
Interviews as Topic
13
Observation
12
Magnetic Resonance Spectroscopy
12
Watchful Waiting
10
radium Ra 223 dichloride
9
darolutamide
9
Androgen Antagonists
9
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
8
Radiosurgery
7
Magnetic Resonance Imaging
7
Brachytherapy
7
abiraterone
6
Specimen Handling
6
Amplified Fragment Length Polymorphism Analysis
6
Triptorelin Pamoate
5
Standard of Care
5
Positron Emission Tomography Computed Tomography
5
Gonadotropin-Releasing Hormone
5
Focus Groups
5
Registries
4
Radiotherapy, Intensity-Modulated
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Prostatic Neoplasms
×
trastuzumab deruxtecan
×
Clear all
NCT07124000
2026-05-01
DP-04
AstraZeneca
Recruiting
100 enrolled